📊 ORIC Key Takeaways
Is Oric Pharmaceuticals, Inc. (ORIC) a Good Investment?
Oric is a development-stage pharmaceutical company with no reported revenue and significant operating losses of -$39.6M annually. Despite a strong balance sheet with $56.4M in cash and minimal debt, the company faces approximately 1.7-2 years of cash runway at current burn rates. Success is entirely dependent on undisclosed pipeline milestones and regulatory approval outcomes.
ORIC remains a pre-revenue biotech with substantial operating and free cash flow losses, but maintains strong liquidity and minimal leverage to fund R&D. While EPS improved year over year, net losses are flat and returns on assets and equity remain deeply negative, implying continued cash burn and potential future financing needs.
Oric Pharmaceuticals, Inc. Key Strengths (ORIC)
- Exceptional balance sheet with 16.33x current ratio and minimal debt (Debt/Equity 0.03x)
- Low financial leverage provides substantial flexibility for continued R&D investment
- Diluted EPS improved 19.7% YoY, indicating cost management and operational discipline
- Very strong liquidity (current and quick ratio ~14x)
- Low leverage (Debt/Equity 0.03x) with minimal interest burden
- Solid solvency buffer (equity $384M vs. liabilities $25M)
ORIC Stock Risks: Oric Pharmaceuticals, Inc. Investment Risks
- Pre-revenue stage with no commercial products generating positive cash flow
- Negative operating cash flow of -$32.4M annually limits financial runway to approximately 1.7-2 years
- Pipeline-dependent business model with unknown clinical trial progress, regulatory approval timeline, and commercialization prospects
- Sustained cash burn (OCF ~$111M outflow; FCF ~$112M outflow)
- No revenue; profitability metrics unavailable and margins effectively negative
- Negative ROE/ROA indicate ongoing value erosion and likely dilution risk
Key Metrics to Watch
- Operating cash burn rate and updated cash runway analysis
- Clinical trial milestone announcements and regulatory approval status
- Revenue recognition or product commercialization timeline
- Cash and marketable securities vs. trailing 12-month operating cash burn (runway)
- R&D and SG&A expense trajectory (operating loss trend)
Oric Pharmaceuticals, Inc. (ORIC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.33x current ratio provides a solid financial cushion.
ORIC Profit Margin, ROE & Profitability Analysis
ORIC vs Healthcare Sector: How Oric Pharmaceuticals, Inc. Compares
How Oric Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oric Pharmaceuticals, Inc. Stock Overvalued? ORIC Valuation Analysis 2026
Based on fundamental analysis, Oric Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oric Pharmaceuticals, Inc. Balance Sheet: ORIC Debt, Cash & Liquidity
ORIC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oric Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.83 indicates the company is currently unprofitable.
ORIC Revenue Growth, EPS Growth & YoY Performance
Oric Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ORIC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oric Pharmaceuticals, Inc. (CIK: 0001796280)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORIC
What is the AI rating for ORIC?
Oric Pharmaceuticals, Inc. (ORIC) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORIC's key strengths?
Claude: Exceptional balance sheet with 16.33x current ratio and minimal debt (Debt/Equity 0.03x). Low financial leverage provides substantial flexibility for continued R&D investment. ChatGPT: Very strong liquidity (current and quick ratio ~14x). Low leverage (Debt/Equity 0.03x) with minimal interest burden.
What are the risks of investing in ORIC?
Claude: Pre-revenue stage with no commercial products generating positive cash flow. Negative operating cash flow of -$32.4M annually limits financial runway to approximately 1.7-2 years. ChatGPT: Sustained cash burn (OCF ~$111M outflow; FCF ~$112M outflow). No revenue; profitability metrics unavailable and margins effectively negative.
What is ORIC's revenue and growth?
Oric Pharmaceuticals, Inc. reported revenue of N/A.
Does ORIC pay dividends?
Oric Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ORIC SEC filings?
Official SEC filings for Oric Pharmaceuticals, Inc. (CIK: 0001796280) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORIC's EPS?
Oric Pharmaceuticals, Inc. has a diluted EPS of $-0.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ORIC's fundamental grade?
Based on our AI fundamental analysis in June 2026, Oric Pharmaceuticals, Inc. has a C grade with 66% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ORIC stock overvalued or undervalued?
Valuation metrics for ORIC: ROE of -8.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ORIC's AI grade for 2026?
Our dual AI analysis gives Oric Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ORIC's free cash flow?
Oric Pharmaceuticals, Inc.'s operating cash flow is $-32.4M, with capital expenditures of $2.0K.
How does ORIC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -8.6% (avg: 15%), current ratio 16.33 (avg: 2).